Report on nationwide pooled data and cohort investigation in UFT phase II study

Cancer Chemotherapy and Pharmacology

Volumn 22, Issue 4, 1988, Pages 333-338

  Ota, Kazuo ^a   Taguchi, Tesuo ^b   Kimura, Kiyoji ^c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Nagoya Memorial Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TEGAFUR; URACIL;

ANEMIA; ANOREXIA; CANCER SURVIVAL; CARCINOMA; DIARRHEA; DRUG EFFICACY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PIGMENTATION; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMPOUNDING; DRUG EVALUATION; HUMAN; NEOPLASMS; TEGAFUR; URACIL;

EID: 0023726563     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00254241     Document Type: Article

References (36)

1. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil
2. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil in rodents
3. Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives
4. Coadministration of thymidine or thymine on antitumor activity of FT-207 or 5-fluorouracil
5. Clinical study on the enhancement of drug delivery into tumor tissue by using UFT
6. Clinical evaluation of schizophylan (SPG) in advanced gastric cancer (the second report). A randomized controlled study
7. Effect of uracil on metabolism of 5-fluorouracil in vitro
8. A randomized trial and adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer
9. Clinical effect of UFT therapy for head and neck cancer
10. 5-Fluorouracil and derivatives in cancer chemotherapy III
11. Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2′-tetrahydrofuryl)-5-fluorouracil
12. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in phase I trial
13. Clinical trial of UFT against recurrent or advanced carcinomas
14. Phase I and preliminary phase II study of co-administration of uracil and FT-207 (UFT therapy)
15. Studies on fluroinated pyrimidines
16. Clinical results of UFT therapy for malignant tumors under cooperative study (phase II study)
17. Phase I and II studies on a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT)
18. Clinical Phase II Study of UFT by Cooperative Study Group
19. Clinical effect of UFT on the advanced cancer with special reference to lung cancer
20. Growth inhibition of a human tumor cell strain by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine reversal studies
21. 5-Fluoropyrimidines as growth inhibitors of microorganisms
22. Potentiation of the teratogenic effects of 5-fluorouracil by natural pyrimidines
23. Clinical trial on the effect of UFT
24. UFT
25. Effect of uracil on the antitumor activity of futraful
26. determination of 5-fluorouracil levels in tumors, blood, and other tissues
27. Phase I study of UFT (uracil plus futraful preparation)
28. End-point results of phase III study of lentinan
29. Clinical studies on the chemotherapy of advanced cancer with UFT (uracil plus futraful preparation)
30. Phase II study of UFT by collaborative study
31. Breast cancer
32. Clinical trial of UFT against advanced cancer
33. Clinical trial on the effect of UFT
34. Clinical results of oral UFT therapy under cooperative study
35. Clinical trial of UFT (uracil-futraful preparation) against malignant tumors